Yuhan Corporation announced Monday that its investigational therapy, YH35995, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Gaucher disease.
This significant designation is awarded to medicines targeting rare diseases, particularly those with limited available treatment options. It provides crucial incentives for pharmaceutical developers, including tax credits for clinical research, waivers for FDA user fees, and a potential seven-year period of market exclusivity post-approval.
Gaucher disease is a rare genetic lysosomal storage disorder, characterized by an enzyme deficiency. This deficiency leads to a range of severe symptoms, such as an enlarged liver and spleen, anemia, thrombocytopenia, and debilitating skeletal complications.
Notably, Type 3 Gaucher disease presents with neurological symptoms and currently lacks any FDA-approved treatment, highlighting a critical unmet medical need for affected patients.
YH35995 is an innovative oral small-molecule drug engineered to inhibit glucosylceramide synthase. Preclinical studies have effectively demonstrated this candidate’s capacity to penetrate the blood-brain barrier and significantly reduce glucosylceramide production, offering promise for neurological manifestations.
Before receiving this crucial FDA designation, Yuhan had already secured approval from Korea’s Ministry of Food and Drug Safety (MFDS) to initiate clinical trials. The company is currently progressing with first-in-human studies, evaluating the safety profile of YH35995 in healthy volunteers.
Yuhan Corp. further stated its commitment to accelerating the global development of YH35995 and advancing robust regulatory strategies, aiming to enhance patient access to this potential treatment.
“This Orphan Drug Designation underscores both the urgent need for novel treatments for Gaucher disease and the significant therapeutic potential of YH35995,” commented Kim Yeol-hong, Head of R&D at Yuhan.
“We are committed to expediting the clinical development of YH35995 in close coordination with global regulatory bodies, with the ultimate goal of delivering impactful new therapeutic options for patients suffering from rare diseases.”
stlee0329
